The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
about
Histone variant H2A.Bbd is associated with active transcription and mRNA processing in human cellsModulating splicing with small molecular inhibitors of the spliceosomeThe genetics of uveal melanoma: current insightsMicrobial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer TreatmentExome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemiaStructural and mechanistic insights into human splicing factor SF3b complex derived using an integrated approach guided by the cryo-EM density mapsIdentification of a small molecule inhibitor that stalls splicing at an early step of spliceosome activation.Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeastTargeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.Rearrangements within human spliceosomes captured after exon ligation.Design, synthesis and initial biological evaluation of a novel pladienolide analog scaffold.Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicingThe Natural Product N-Palmitoyl-l-leucine Selectively Inhibits Late Assembly of Human SpliceosomesPharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates.Small-scale nuclear extracts for functional assays of gene-expression machineries.The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.Small Molecule Modulators of Pre-mRNA Splicing in Cancer TherapySpliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaInterchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stagesFunctional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.Intronic cleavage and polyadenylation regulates gene expression during DNA damage response through U1 snRNAThe zebrafish sf3b1b460 mutant reveals differential requirements for the sf3b1 pre-mRNA processing gene during neural crest development.Test-firing ammunition for spliceosome inhibition in cancer.Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.Splicing in oncogenesis and tumor suppression.The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.Next-generation sequencing reveals the secrets of the chronic lymphocytic leukemia genome.Alternative splicing in cancer: implications for biology and therapy.Splice factor mutations and alternative splicing as drivers of hematopoietic malignancy.Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.Evidence that C9ORF72 Dipeptide Repeat Proteins Associate with U2 snRNP to Cause Mis-splicing in ALS/FTD Patients.Therapeutic targeting of splicing in cancer.Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.Splicing factor gene mutations in hematologic malignancies.Modulation of aberrant splicing in human RNA diseases by chemical compounds.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Biological validation that SF3b is a target of the antitumor macrolide pladienolide.Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer.
P2860
Q24293198-0C8F7900-27D8-4237-A8F0-8AE578B0E8D2Q26738664-10F87B08-E91E-4C9E-A8CC-A0C1B3204E6EQ28073150-6ADB0C70-5FC4-41E3-B5D1-6F2EABD2A147Q28074931-E3148F35-C332-4379-9EF3-224435F6BAB1Q28255147-109F6F52-708A-4828-9A96-CA44147763F4Q28315106-0F7D3BFC-B023-48DF-A454-76C048363CD9Q30360791-185FA228-CF42-40AB-8D02-B41EB5A5CAE5Q30420265-FD853A34-74BD-4759-8138-AE46A668BE59Q33635951-0991CF4C-E372-41E8-8013-439BB52ED8E9Q34047259-386B2591-43C7-4015-A655-BDB1AAD541E8Q34324094-E06AF786-D161-48AD-B5A1-F221A6EEE1A2Q35209996-057D6F00-01AF-4BAC-BAA1-5F772AD218B0Q35541632-319BBBB1-CFAD-4849-B687-9130DAB18C30Q35789105-140302C4-886B-4094-AA2E-5F4A5FED1590Q35822289-E887D524-01E7-4134-91F1-5936D155FEB7Q36317420-86FABFF8-7026-45E7-A274-213E07299BC9Q36410173-93EC6D93-8569-452B-AB6D-22B4EB85D3C7Q36447664-5B264C02-6AFD-4D1B-89B2-65133F221756Q36498395-3D45CFE3-032F-49EA-80CA-4E099C0E96B1Q36566585-24DD2272-E6A1-4087-A27F-268B839DF183Q36584775-1AFF0262-962E-43FC-AACF-51B5E8F31531Q36984373-CCCBFF24-2618-4985-9297-0D5C6B8CE56AQ37001441-9E91BB48-7F64-4E7F-8F54-FAF06850AAA6Q37114469-061D78DE-F8A7-4942-89A4-408D72F3D318Q37339144-ED13AAE8-8F3D-4A71-89D6-E44B1C73A531Q37511674-2B9E7C3B-D259-4E47-8742-5403EB4161E0Q38018123-B55F2230-5149-444F-9A5E-50D2DB363C5FQ38033985-CEAF6ED3-7320-4282-8B64-014C760EA6F4Q38036607-D861FC37-D3BC-4E98-93B8-0DB8325FED75Q38179828-34459A8C-A810-488F-9BAD-43AD84215783Q38289057-F9BFA52B-3B29-44C3-96E9-F7897E177F90Q38712211-35225640-F9FF-4448-9A52-A94A82F79600Q38725663-C898E91B-23C2-472D-AD33-293CBEDC6026Q38948363-8E50CD09-B853-4DBE-B685-D0568A4DC17DQ38972458-2EC27A57-5F16-43AD-8E4E-8C587D1D4489Q39035441-8AD117F5-4424-41E8-AAF7-B17344CFA579Q39212263-7DE67009-3D08-4B33-99A3-C2ED2B1D33D0Q39279998-C6B4C827-8C75-4092-856F-70CD1575FE98Q39461667-F6D49FF0-D22E-423A-9E2E-FBD1EF35B53DQ39803624-91ABAC20-3CCD-4426-8E1E-B62541D929DB
P2860
The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@ast
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@en
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@nl
type
label
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@ast
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@en
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@nl
prefLabel
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@ast
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@en
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@nl
P2093
P2860
P356
P1433
P1476
The anti-tumor drug E7107 reve ...... e branch point-binding region.
@en
P2093
Eric G Folco
Kaitlyn E Coil
Robin Reed
P2860
P304
P356
10.1101/GAD.2009411
P577
2011-03-01T00:00:00Z